Key Drivers
- Ample liquidity
- Zero revenue
- Large cash burn
AIAI Summary
DSGN is now a binary, event‑driven biotech: its ~$220M liquidity meaningfully reduces near‑term financing risk so valuation will be decided by clinical execution (DT‑818 dosing H1 2026 and RESTORE‑FA/DT‑168 data) rather than balance‑sheet concerns. Actionable: treat it as a catalyst play—monitor DT‑818 dosing/enrollment milestones, quarterly burn (runway <12–18 months is a sell‑risk), and cut exposure if DT‑818 dosing slips past H1 2026 or if early safety/PK signals disappoint.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Ample liquidity
- •Zero revenue
- •Large cash burn
DSGN has extremely strong liquidity and minimal debt but no revenue and heavy operating cash burn, forcing reliance on ongoing financing or a material operating turnaround.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Failed breakout
- •Low volatility
Over the last month DSGN drifted up ~2%, repeatedly defending $10.00–$10.05 but failing to sustain a $11.04 breakout, indicating fragile momentum and limited upside until volume-backed follow-through above $11.00.
Spike to $11.04 then pullback to low-$10s suggests short-term mean reversion
Sentiment & News
Key News Insights:
- •DT-818 dosing
- •Trials ongoing
- •Financial alignment
Design Therapeutics reported Q4/2025 results while confirming ongoing DT-216P2 and DT-168 trials and announcing planned DT-818 dosing in H1 2026, underscoring pipeline momentum tied to its fiscal update.
The planned DT-818 dosing and continued trial progress should bolster investor sentiment short-term, but material share movement will depend on upcoming clinical readouts and execution
Similar Companies in Healthcare
Other companies in the same sector with AI ratings